%0 Journal Article
%T Utilidad del infliximab en el tratamiento de la amiloidosis secundaria en la enfermedad de Crohn
%A Cabezuelo
%A Juan B.
%A Egea
%A Juan P.
%A Ramos
%A Fernanda
%A Torrella
%A Emilio
%A Muray
%A Salom¨¦
%A Alc¨¢zar
%A Concepci¨®n
%J Nefrolog¨ªa (Madrid)
%D 2012
%I Scientific Electronic Library Online
%X secondary amyloidosis (aa) is a severe complication of progressed crohn's disease (cd) for which no effective treatment exists. we present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with aa amyloid nephropathy and oligosymptomatic cd. he was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to cd.
%K infliximab
%K secondary amyloidosis
%K crohn's disease.
%U http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S0211-69952012000500016&lng=en&nrm=iso&tlng=en